Abstracts tagged "Clinical Response"

Abstract Number: 1352 • 2013 ACR/ARHP Annual Meeting
What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Soo-Kyung Cho^1,2, Yoon-Kyoung Sung^1,2, Jeeseon Shim³, Chan-Bum Choi^4,5, Jung-Yoon Choe⁶, Won Tae Chung⁷, Seung-Jae Hong⁸, Jae-Bum Jun⁵, Tae-Hwan Kim⁹, Tae-Jong Kim¹⁰, Eun-Mi Koh¹¹, Jisoo Lee¹², Shin-Seok Lee¹⁰, Sung Won Lee¹³, Dae-Hyun Yoo⁵ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹²Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹³Rheumatology, Dong-A University Hospital, Busan, South Korea
Background/Purpose: Clinical remission has now become the treatment goal in rheumatoid arthritis (RA), but it is not common in clinical practice. This study aimed to…
Abstract Number: 1312 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized Trial
Karen Hambardzumyan¹, Rebecca Bolce², Scott E. Cruickshank³, Eric H. Sasso², David Chernoff², Kristina Forslind⁴, Saedis Saevarsdottir⁵, Ingemar F. Petersson⁶, Pierre Geborek⁷, Sofia Ernestam⁸ and Ronald F van Vollenhoven⁹, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Scott E. Cruickshank and Associates, Inc., Santa Barbara, CA, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Lund University, Lund, Sweden, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁸Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, ⁹ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), predictors of radiographic damage would be useful for optimal targeting of therapy. It has been suggested that combining various…
Abstract Number: 876 • 2013 ACR/ARHP Annual Meeting
Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling
Jason Ptacek¹, Rachael Hawtin², Brent Louie¹, Erik Evensen¹, James Cordeiro¹, Barbara Mittleman¹, Michelle Atallah¹, Alessandra Cesano², Clifton O. Bingham III³, Stacey Cofield⁴, Jeffrey R. Curtis⁵, Maria I. Danila⁴, Richard A. Furie⁶, MC Genovese⁷, Marc C. Levesque⁸, Larry W. Moreland⁸, Peter A. Nigrovic⁹, James R. O'Dell¹⁰, William H. Robinson¹¹, Nancy A. Shadick⁹, E. William St Clair¹², Christopher C. Striebich¹³, Geoffrey M Thiele¹⁴, Peter K. Gregersen⁶ and S. Louis Bridges Jr.⁴, ¹Nodality, Inc., South San Francisco, CA, ²Nodality Inc., South San Francisco, CA, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁷Stanford University, Palo Alto, CA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital/Harvard University, Cambridge, MA, ¹⁰Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹¹VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell…
Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Carol A. Wallace¹, Edward H. Giannini², Steven J. Spalding³, Philip J. Hashkes⁴, Kathleen M. O'Neil⁵, Andrew S. Zeft⁶, Ilona S. Szer⁷, Sarah Ringold⁸, Hermine Brunner⁹, Laura E. Schanberg¹⁰, Robert P. Sundel¹¹, Diana Milojevic¹², Marilynn G. Punaro¹³, Peter Chira¹⁴, Beth S. Gottlieb¹⁵, Gloria C. Higgins¹⁶, Norman T. Ilowite¹⁷, Yukiko Kimura¹⁸, Anne Johnson⁹, Bin Huang¹⁹ and Daniel J. Lovell², ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, ⁸Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Pediatrics, Duke University Medical Center, Durham, NC, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁴Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ¹⁸Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Julie Azaïs¹, Thomas Barnetche², Pascale Vergne-Salle³, Christine Bonnet⁴, Carine Dufauret-Lombard⁵, Richard Treves⁶ and Philippe Bertin⁷, ¹Rheumatology department, CHU Dupuytren Limoges, Limoges, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, CHU Dupuytren Limoges, limoges, France, ⁴department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁵Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁶Department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁷Service De Rhumatologie, CHU Dupuytren Limoges, Limoges, France
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…
Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Kim Hørslev-Petersen¹, Merete Lund Hetland², Peter Junker³, Jan Pødenphant⁴, Torkell Ellingsen⁵, Palle Ahlqvist⁶, Hanne M. Lindegaard⁷, Asta Linauskas⁸, Annette Schlemmer⁹, Mette Y. Dam¹⁰, Ib Hansen¹¹, Tine Lottenburger⁶, Anette Jørgensen¹², Sophine B. Krintel¹³, Johnny Raun¹⁴, Christian G. Ammitzbøll¹⁰, Julia Johansen¹³, Mikkel Østergaard¹⁵ and Kristian Stengaard-Pedersen¹⁰, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Copenhagen University at Gentofte, Hellerup, Denmark, ⁵Silkeborg Regional Hospital, Silkeborg, Denmark, ⁶University of Southern Denmark, Vejle, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Vendsyssel Hospital, Hjørring, Denmark, ⁹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁰Arhus University Hospital, Aarhus, Denmark, ¹¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹³Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁴University of Southern Denmark, Graasten, Denmark, ¹⁵Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…
Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴, Dan Nemes⁵, Rodica Chirieac⁶, Paulina Ciurea⁷, Maria Suta⁸, Andra Balanescu⁹, Eugenia Mociran¹⁰ and Elena Rezus¹¹, ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁶C.M.I. Rodica Chirieac, Iasi, Romania, ⁷Emergency County Hospital, Craiova, Romania, ⁸Emergency County Hospital, Constanta, Romania, ⁹Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ¹⁰Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…
Abstract Number: 2377 • 2013 ACR/ARHP Annual Meeting
Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Wendy White¹, Patricia Ryan², Xiang Guo³, Dominic Sinibaldi⁴, Gopi Ranganna⁵, Alex Godwood⁶, Didier Saurigny⁶, David Close⁶, Steve Eck⁴, Dee Wilkins¹, Lorin Roskos⁷, Matthew A. Sleeman⁸, Wanying Li⁹, Guy Cavet⁹ and Nadine A. Defranoux⁹, ¹Translational Sciences, MedImmune, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune LLC, Gaithersburg, MD, ⁴MedImmune, LLC, Gaithersburg, MD, ⁵Clinical Development, MedImmune, LLC, Cambridge, United Kingdom, ⁶MedImmune, Ltd, Cambridge, United Kingdom, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ⁹Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through effects on macrophages and neutrophils. Mavrilimumab (CAM-3001) is a human monoclonal…
Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Catalin Codreanu¹, Ioan Ancuta² and Ruxandra Ionescu³, ¹Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ²“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
M. C. Genovese¹, R. F. van Vollenhoven², B. Wilkinson³, L. Wang³, S. H. Zwillich³, D. Gruben³, B. Benda⁴ and T. V. Jones⁴, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Josef S. Smolen¹, Ronald van Vollenhoven², Arthur Kavanaugh³, Vibeke Strand⁴, Jiri Vencovsky⁵, Michael H. Schiff⁶, Robert Landewé⁷, Boulos Haraoui⁸, Susan Walker⁹ and Désirée van der Heijde¹⁰, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁵Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹UCB Pharma, Raleigh, NC, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].